These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 19789949)

  • 1. Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.
    Yoshimoto N; Yamashita T; Fujita T; Hayashi H; Tsunoda N; Kimura M; Tsuzuki N; Yamashita H; Toyama T; Kondo N; Iwata H
    Breast Cancer; 2010 Oct; 17(4):298-302. PubMed ID: 19789949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
    Kang YK; Lee SS; Yoon DH; Lee SY; Chun YJ; Kim MS; Ryu MH; Chang HM; Lee JL; Kim TW
    J Clin Oncol; 2010 Aug; 28(24):3824-9. PubMed ID: 20625131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia.
    Chalermchai T; Tantiphlachiva K; Suwanrusme H; Voravud N; Sriuranpong V
    Asia Pac J Clin Oncol; 2010 Sep; 6(3):155-60. PubMed ID: 20887495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of low-dose capecitabine monotherapy for metastatic breast cancer.
    Taguchi T; Nakayama T; Masuda N; Yoshidome K; Akagi K; Nishida Y; Yoshikawa Y; Ogino N; Abe C; Sakamoto J; Noguchi S;
    Chemotherapy; 2010; 56(2):166-70. PubMed ID: 20407245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A woman with palmar and plantar hyperpigmentation].
    van Tienhoven G; Wilmink JW
    Ned Tijdschr Geneeskd; 2011; 155(45):A4100. PubMed ID: 22085578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
    Caronia D; Martin M; Sastre J; de la Torre J; García-Sáenz JA; Alonso MR; Moreno LT; Pita G; Díaz-Rubio E; Benítez J; González-Neira A
    Clin Cancer Res; 2011 Apr; 17(7):2006-13. PubMed ID: 21325291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer.
    Blum JL; Barrios CH; Feldman N; Verma S; McKenna EF; Lee LF; Scotto N; Gralow J
    Breast Cancer Res Treat; 2012 Dec; 136(3):777-88. PubMed ID: 23104222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome?
    Do JE; Kim YC
    Clin Exp Dermatol; 2007 Sep; 32(5):519-21. PubMed ID: 17509060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy.
    Son HS; Lee WY; Lee WS; Yun SH; Chun HK
    Yonsei Med J; 2009 Dec; 50(6):796-802. PubMed ID: 20046420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High frequency of hand foot syndrome with capecitabine.
    Kamil M; Haron M; Yosuff N; Khalid I; Azman N
    J Coll Physicians Surg Pak; 2010 Jun; 20(6):421-2. PubMed ID: 20642979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of hand-foot syndrome induced by capecitabine.
    Gressett SM; Stanford BL; Hardwicke F
    J Oncol Pharm Pract; 2006 Sep; 12(3):131-41. PubMed ID: 17022868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine.
    Saif MW; Elfiky A; Diasio R
    Clin Colorectal Cancer; 2006 Sep; 6(3):219-23. PubMed ID: 17026792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer.
    Chua D; Wei WI; Sham JS; Au GK
    Jpn J Clin Oncol; 2008 Apr; 38(4):244-9. PubMed ID: 18407933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Management of hand-foot syndrome in patient treated with capecitabine].
    Fujii C; Anami S; Fujino M; Yasui Y; Fujita M; Inoue M; Nakayama T; Kamigaki S; Tatsuta M; Furukawa H
    Gan To Kagaku Ryoho; 2008 Aug; 35(8):1357-60. PubMed ID: 18701848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Breast cancer and the hand-foot syndrome].
    Llambrich C; Falcou MC; De Rycke Y; Cottu P; Carrié S; Medjbari M
    Soins; 2012 Jun; (766):25-8. PubMed ID: 22870762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients.
    von Gruenigen V; Frasure H; Fusco N; DeBernardo R; Eldermire E; Eaton S; Waggoner S
    Cancer; 2010 Oct; 116(20):4735-43. PubMed ID: 20629022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
    Hofheinz RD; Gencer D; Schulz H; Stahl M; Hegewisch-Becker S; Loeffler LM; Kronawitter U; Bolz G; Potenberg J; Tauchert F; Al-Batran SE; Schneeweiss A
    J Clin Oncol; 2015 Aug; 33(22):2444-9. PubMed ID: 26124485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capecitabine and hand-foot syndrome.
    Saif MW
    Expert Opin Drug Saf; 2011 Mar; 10(2):159-69. PubMed ID: 21174613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Assessment of hand-foot syndrome in cancer outpatients undergoing chemotherapy].
    Takeda K; Shigematsu T; Shirai M; Yamagiwa K; Amamori K; Sunda K; Yamanda T
    Gan To Kagaku Ryoho; 2012 Dec; 39 Suppl 1():74-6. PubMed ID: 23268906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.